Philip A. Sharp, Director at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 50,000 shares at $40.16 ($2.0M) on 2017-02-01, disclosed to the SEC on 2017-02-03.
Open-market sale of $2.0M ALNY by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.72 | 20,171 | $801K | 40.3% |
| 2 | $39.72 | 20,171 | $801K | 40.3% |
| 3 | $40.16 | 4,829 | $194K | 9.7% |
| 4 | $40.16 | 4,829 | $194K | 9.7% |
| Total | $39.80 avg | 50,000 | $2.0M | 100% |
| Filing → |
| ALNY | SELL | 2018-03-13 | $1.9M | — | Filing → |
| ALNY | SELL | 2017-01-27 | $569K | — | Filing → |
| ALNY | SELL | 2017-01-20 | $804K | — | Filing → |